3rd Quarter - Report

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

ACA Implementation Issues 21st Century Cures Initiative (Chairman Upton) Biosimilars

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax Reform Act of 2014 (Chairman Camp Draft) Corporate Tax Reform proposals Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Patent Reform: Schumer/Cornyn Compromise Draft Patent Transparency and Improvements Act, S. 1720 Patent Abuse Reduction Act, S. 1013

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1013 (113th), S. 1720 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.